* ISOPTO-MAXITROL Sterile Eye (Ophthalmic) Preparation. 5 ml Drop-Trainer Dispenser. |
* Composition (Ingredients): |
– Active: Neomycin (present as Sulfate) 3.5 mg / mL, Polymyxin B Sulfate 6,000 units/mL, Dexamethasone 0.1%. |
– Vehicle: Hydroxypropyl Methylcellulose (4,000 cps) 0.5%. |
– Preservative: Benzalkonium Chloride 0.004%. |
* Indications: |
& Eye: In the management of infectious ocular inflammations produced by organisms which are sensitive |
& to the antibiotics, Neomycin Sulfate and Polymyxin B sulfate. Acute or chronic nonpurulent conjunctivitis, |
& blepharoconjunctivitis and keratoconjunctivitis; nonspecific superficial keratitis; deep keratitis; acne |
& rosacea keratitis; iridocyclitis mild acute iritis; recurrent marginal ulceration and corneal ulcer (use with |
& care in those diseases causing thining of cornea because of the danger of proliferation); nonpurulent |
& blepharitis; scleritis; episcleritis; scleroconjunctivitis; herpes zoster ophthalmicus (do not use in Herpes |
& simplex); and post-operatively to aid in the prevention of ophthalmic cases of infections. |
* Contraindications: |
& This drug is contraindicated in tuberculosis, fungal and most viral lesions of eye (herpes simplex/dentritic |
& keratitis); varicella; acute purulent conjunctivitis and acute purulent blepharitis, aural fungal infection. |
* Precautions: |
– Extended use of topical steroid therapy may cause increased intraocular pressure in certain individuals. |
& It is advisable that intraocular pressure be checked frequently. |
– In those diseases causing thinning of the cornea, perforation has been known to occur with the use of |
& topical steroids. |
– Prolonged use may result in overgorwth of non-susceptible organisms, including fungi. Appropriate measures |
& should be taken when this occurs. A few individuals may be sensitive to one or more components of this |
& product. If any reactions indicating sensitivity are observed, discontinue use. |
– Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of |
& their use in pregnancy has not absolutely been established. Therefore it is advisable not to use this product |
& for long-term treatments of pregnant patients. |
* Dosage and Administration: |
& Eye: one or two drops topically in the conjunctival sac(s) 4 to 6 times daily. Dosage may be reduced after |
& 3 to 4 days when satisfactory improvement has been obtained. Treatment should be repeated as long as |
& necessary following physician’s advice. |
* Shake Well Before Using. |
* Store upright. Do not store above 25 degrees C. Do not refrigerate or freeze. |
* ALCON-COUVREUR – Belgium. المستوردون: الشركة المتحدة للتجارة والتوزيع |
الوزن | 100 kg |
---|
POLYMYXIN-B + NEOMYCIN + DEXAMETHASONE